Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19)
https://doi.org/10.22416/1382-4376-2022-32-1-41-45
Abstract
Aim. To study the effectiveness of Kolofort® (affinally purified antibodies to tumor necrosis factor α, to the brain-specific protein S-100 and to histamine) in patients with various variants of irritable bowel syndrome (IBS) that developed after a new coronavirus infection (COVID-19).
Materials and methods. Clinical and laboratory data of 32 patients with IBS who had a history of COVID-19 pneumonia were analyzed. Course therapy with Kolofort® is prescribed according to the standard scheme for 3 months. Before and after treatment, the dynamics of the symptoms of IBS was assessed according to the questionnaire, the dynamics of anxiety was assessed according to the Hamilton scale.
Results. There were a statistically significant decrease in the severity of IBS symptoms (normalization of the consistency of the stool, cessation of flatulence, a decrease in abdominal pain; p < 0.05) and a decrease in anxiety after the end of treatment.
Conclusions. Kolofort® may be effective in eliminating the symptoms of post-infectious IBS and anxiety that developed after COVID-19.
About the Author
R. G. Myazin
Volgograd State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Roman G. Myazin — Сand. Sci. (Med.), Assistant Professor, department of internal medicine, Volgograd State Medical University.
400131, Volgograd, Pavshih Bortsov sq., 1.
References
1. Drossman D.A., Hasler W.L. Rome IV — Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology. 2016;150(6):1262–79. DOI: 10.1053/j.gastro.2016.03.035
2. Ivashkin V.T., Maev I.V., Shelygin Yu.A., Baranskaya E.K., Belous S.S., Belousova E.A., et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Rus J Gastroenterol Hepatol Coloproctol. 2021;31(5):74–95 (In Russ.) DOI: 10.22416/1382-4376-2021-31-5-74-95
3. Wang C., Pan R., Wan X., Tan Y., Xu L., Ho C.S., Ho R.C. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020;17(5):1729. DOI: 10.3390/ijerph17051729
4. Ma C., Cong Y., Zhang H. COVID-19 and the Digestive System. Am J Gastroenterol. 2020;00:1–4. DOI: 10.14309/ajg.0000000000000691
5. Zuo T., Liu Q., Zhang F., Lui G.C., Tso E.Y., Yeoh Y.K., et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021;70(2):276–84. DOI: 10.1136/gutjnl-2020-322294
6. Farsi Y., Tahvildari A., Arbabi M., Vazife F., Sechi L.A., Shahidi Bonjar A.H., et al. Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review. Front Cell Infect Microbiol. 2022;12:804644. DOI: 10.3389/fcimb.2022.804644
7. Gaus O.V., Livzan M.A. Post-infectious IBS: a new look at an old problem. Effective pharmacotherapy. 2021;17(16):108–13 (In Russ.). DOI: 10.33978/2307-3586-2021-17-16-108-113
8. Surdea-Blaga T., Băban A., Dumitrascu D.L. Psychosocial determinants of irritable bowel syndrome. World J Gastroenterol. 2012;18(7):616–26. DOI: 10.3748/wjg.v18.i7.616
9. Tsukanov V.V., Rzhavicheva O.S., Vasjutin A.V., Dunaevskaja O.V., Tonkih Yu.L., Bronnikova E.P. Efficacy of Kolofort for the treatment of patients with irritable bowel syndrome. Ter Arkh. 2016;88(8):40–5 (In Russ.). DOI: 10.17116/terarkh201688840-45
10. Lacy B.E., Pimentel M., Brenner D.M., Chey W.D., Keefer L.A., Long M.D., Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17–44. DOI: 10.14309/ajg.0000000000001036
11. Sheptulin A.A., Vize-Khripunova M.A. Postinfectious Irritable Bowel Syndrome: Polemic and Open Issues. Rus J Gastroenterol Hepatol Coloproctol. 2021;31(6):41–6 (In Russ.). DOI: 10.22416/1382-4376-2021-31-6-41-46
12. Ghoshal U.C., Ghoshal U., Rahman M.M., Mathur A., Rai S., Akhter M., et al. Post-infection functional gastrointestinal disorders following coronavirus disease-19: A case-control study. J Gastroenterol Hepatol. 2022;37(3):489–98. DOI: 10.1111/jgh.15717
Review
For citations:
Myazin R.G. Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(1):41-45. https://doi.org/10.22416/1382-4376-2022-32-1-41-45
Views:
1217
Email this article 
